# Sermorelin vs Tesamorelin: GHRH Analogs Compared > Sermorelin vs tesamorelin: both are GHRH analogs, but sermorelin is the short-lived native GHRH(1-29) while tesamorelin is the stabilized, longer-acting analog that carries most of the body-composition evidence. Two members of the same family — the native short-acting fragment and its stabilized, longer-lasting relative — and where the evidence concentrates for each. ## The gist Sermorelin vs tesamorelin is a comparison within one family. Both are GHRH analogs — synthetic versions of the brain's "make growth hormone" signal — and both prompt the pituitary to release the body's own GH. The difference is durability: sermorelin is the native GHRH(1-29) fragment that clears the blood in about 10-12 minutes [3], while tesamorelin is a stabilized, longer-acting analog engineered to last [11]. That extra duration is part of why tesamorelin, not sermorelin, carries most of the body-composition evidence [7]. If you remember one thing from this page, make it that: same family and same receptor, but the fat-loss numbers people quote almost always come from the longer-acting cousin, not from sermorelin itself. ## Same family, different durability Sermorelin is GHRH(1-29): the short, fully active N-terminal fragment of natural GHRH, rapidly eliminated with a plasma half-life on the order of ~10-12 minutes, though a single dose keeps GH elevated for roughly 3 hours [3]. Tesamorelin is a stabilized synthetic GHRH analog reviewed as a growth-hormone-releasing factor analogue for HIV-associated lipodystrophy [11]. The native fragment's brevity is exactly what motivated stabilized analogs — structural strategies such as a D-Ala2 substitution and serum-albumin-binding chemistry extend a peptide's half-life and reduce clearance [11]. Both act at the same GHRH receptor and preserve the pulsatile, feedback-regulated character of GH release [4][15]. The practical consequence of that durability gap is dosing cadence and exposure. A short-acting fragment delivers a pulse and clears; a stabilized analog sustains a GHRH signal far longer, which changes how the axis is engaged over a day. This is why the two molecules, despite sharing a receptor and a mechanism, accumulated different clinical datasets — the longer-acting analog was the one carried into multi-week body-composition and cognition trials [6][7]. Same family, same target, different pharmacokinetics, and as a result, different evidence. ## Where the evidence concentrates The two molecules' datasets differ. Sermorelin's strongest human evidence is its historical pediatric GH-deficiency efficacy — first-year height velocity rising from ~4.1 to ~7-8 cm/year [1] — and the 14-day GH/IGF-1 reversal in older men [2]. Tesamorelin carries the body-composition record: significant visceral-fat reduction versus placebo in HIV-associated fat accumulation [7], metabolic and body-composition effects in obese adults with reduced GH secretion [9], and the SMART-trial cognition-and-body-fat result in older adults [6]. When a "sermorelin for fat loss" claim cites visceral-fat data, that data usually belongs to tesamorelin — a distinction this comparison keeps explicit. An editorial frames sermorelin's appeal as a physiologic secretagogue that preserves the body's own pulsatile GH release, an argument about mechanism rather than about superior body-composition outcomes [4]. ## How does sermorelin compare to CJC-1295? Both are GHRH analogs, but sermorelin is the native, short-lived 1-29 sequence (~10-12 min plasma half-life) [3], whereas longer-acting analogs are engineered to persist. The structure-activity basis is the same family of strategies that extends duration — a D-Ala2 substitution and serum-albumin-binding (DAC) chemistry that prolong half-life and reduce clearance [11]. The practical contrast is duration of action at the same receptor, not a different mechanism. ## Sermorelin vs ipamorelin: what is the difference? They act on different receptors. Sermorelin is a GHRH analog working at the GHRH receptor; ipamorelin is a growth-hormone-releasing peptide (GHRP) acting on the ghrelin/GHS receptor [15]. The two mechanisms are complementary — separate pathways onto the same somatotroph — which is why GHRH analogs and GHRPs are sometimes studied together rather than as substitutes. ## How does sermorelin differ from direct HGH injections? Direct HGH supplies growth hormone from outside and can override the body's feedback; sermorelin instead prompts the pituitary to make its own GH, preserving pulsatility and somatostatin/IGF-1 feedback [4][15]. An editorial argues this is a more physiologic approach to adult-onset growth hormone insufficiency, because the axis keeps governing itself rather than being bypassed [4]. ## Physiologic by design, but not unregulated The recurring theme across these comparisons is that GHRH(1-29) and its relatives work with the somatotropic axis rather than around it. Because the IGF-1 rise in the GHRH-analog SMART trial stayed within the physiologic range [6], and because GHRH(1-29) in older men brought GH/IGF-1 toward — not past — youthful levels [2], the class is often described as physiologic. That framing should not be mistaken for "unregulated by anyone." Growth-hormone secretagogues, including GHRH analogs, are prohibited in sport by WADA, and dedicated detection methods exist for them. "Physiologic mechanism" is a statement about how the molecule acts on the pituitary; it is not a statement about legal status in competition, and it is not a clearance for human use outside research. ## Which one the studies actually used A practical reading rule closes the comparison: when a result involves visceral fat, percent body fat, HIV-associated lipodystrophy, or a 20-week cognition endpoint, the molecule under study is the stabilized analog tesamorelin [6][7][9][11]. When a result involves first-year height velocity in children or a 14-day GH/IGF-1 shift in older men, the molecule is GHRH(1-29) itself [1][2]. Pharmacokinetic facts — the ~10-12 minute plasma half-life with GH elevated ~3 hours, and the dose-response across intravenous, subcutaneous, and intranasal routes — were established with the native fragment and its close analog [3][14]. Keeping that map in view is the surest way to read "sermorelin" claims without inheriting tesamorelin's evidence by accident. --- The sermorelin record filed cell by cell on a research board — every GH and IGF-1 figure carried back to its study, the body-composition evidence marked as tesamorelin where it belongs, and the empty long-term-safety cell left openly unfilled; no clinic behind the board and nothing here dosed, dispensed, or sold.